BDBM384407 US10590114, No. 93::US11111235, No. 93::US11591316, Compound 93::US9932325, Example 93

SMILES CCNc1nc(Nc2cn(nc2C2CC2)C(C)(C)C#N)ncc1Br

InChI Key InChIKey=ADCVJXFOMVRRJJ-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 384407   

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Denali Therapautics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50:  1.87nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50:  1.87nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50: <30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent